Guest blog: Cell therapy approval and reimbursement must pace in synch within the modern scenarios

Cell therapy approval and reimbursement must pace in synch within the modern scenarios. Gil Van Bokkelen, Athersys CEO, and Micheal Werner, Alliance for Regenerative Medicine Co-founder and Executive Director, explained the requirements for the delicate interphase between regulatory front and business reimbursement for a stem cell therapy company. Regulatory process complexity versus reimbursement presents a major challenge: these business components …